Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Description of the incidence and risk of co-morbidities developing subsequent to cancer treatment aids in creating tailored survivorship care
New indication concerns maintenance treatment of adults with advanced ovarian cancer who are in response following completion of first-line platinum-based chemotherapy
New indication concerns a combination with bevacizumab for the treatment of adults with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy
New indication concerns their combination with 2 cycles of platinum-based chemotherapy in first-line treatment of metastatic NSCLC without sensitising EGFR mutation or ALK translocation
New indications concern the maintenance treatment in combination with bevacizumab of ovarian cancer with HRD positive status and monotherapy of mCRPC with BRCA1/2 mutations
Whether women with cervical cancer benefit from completion of radical surgery upon intraoperative determination of N1 positivity had been controversial
Identification of the most frequently mutated genes in metastatic renal cell carcinoma
Gene signatures and tumour microenvironments were identified that associate with nivolumab outcomes
Application of the Global Leadership Initiative on Malnutrition criteria
The abundance and heterogeneity of quality of life literature regarding immune checkpoint inhibitors can make patient education difficult
Rheumatic immune-related adverse events resemble classical rheumatic and musculoskeletal diseases with distinct clinical and laboratory characteristics
The best response in sarcoma patients treated with pembrolizumab was partial response in the AcSé Pembrolizumab study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
